A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
City of Hope Medical Center
Seagen Inc.
Novartis
Elicio Therapeutics
Columbia University
Revolution Medicines, Inc.
UTC Therapeutics Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Corvus Pharmaceuticals, Inc.
Chongqing Precision Biotech Co., Ltd
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Novartis
MacroGenics
Abramson Cancer Center at Penn Medicine
Northwestern University
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Cancer Research UK
National Cancer Institute (NCI)
Case Comprehensive Cancer Center